Mexico City, 24 July 2019 – South African study shows that dolutegravir-containing regimens perform as well as the current efavirenz-containing one used for first-line antiretroviral treatment (ART) in South Africa and most of Africa. These data are important in showing how dolutegravir and a new form of tenofovir (called tenofovir alafenamide or TAF) perform in African populations, and in providing the scientific backing for the move to dolutegravir-containing regimens from efavirenz-containing ones worldwide. The initial study results are also published today in the most prestigious medical journal in the world, The New England Journal of Medicine.
ECHO finds no substantial difference in HIV risk among DMPA-IM,copper IUD, and LNG implant users. DURBAN (South Africa) 13 June 2019 – A pivotal clinical trial to address a long-standing question about the relationship between hormonal contraceptive use and the risk of HIV acquisition has found no substantial difference in HIV risk among 7,829 African women who were randomly assigned to use one of three highly effective methods of contraception.
Wits RHI is proud to announce the launch of a USAID-funded five year (2018 - 2023) School Based HIV and Gender Based Violence (GBV) Prevention Programme.Wits RHI will work directly with the Department of Basic Education (DBE) to reduce the incidence of HIV, tuberculosis (TB) infections and violence among in-school adolescent girls and boys, aged between 9 – 19 years, across five provinces in South Africa.
Wits RHI is the successful recipient of two awards from the Bill and Melinda Gates Foundation and the National Health and Medical Research Council of Australia for over the next five years. These will fund a study to evaluate the impact of 2-dose and 1-dose human papillomavirus vaccination schedules on community level HPV prevalence in South African adolescent girls. Cervical cancer is caused by human papillomavirus (HPV) and is the leading cancer among women aged 15–44.
The Wits RHI Key Populations Programme is the successful recipient of a 5-year USAID Award for advancing the South African HIV Response for Key Populations, Sex Workers, and Transgender individuals. Sex workers and transgender individuals remain marginalised in public healthcare. In South Africa, between 40 percent and 88 percent of sex workers are HIV positive. Transgender women globally are 50 times more likely to be HIV positive than the general population. This award will change the status quo for key populations in South Africa through increasing access to health care and enhancing competency of health service providers to tailor responses to their needs.
The Minister of Health, Dr Aaron Motsoaledi, has appointed members of the South African Health Products Regulatory Authority (SAHPRA) Board. SAHPRA replaces the Medicines Control Council (MCC). The scope of the new Authority has expanded to include not only medicines, but also medical devices including in vitro diagnostics, and aspects of radiation control.
A highly effective oral medication to prevent HIV will be provided to young women in South Africa at high risk of getting the virus, as part of a sexual and reproductive health access project launched today by the Wits Reproductive Health and HIV Institute (Wits RHI) and Unitaid.
The development of vaccines has greatly impacted on the reduction of mortality rates across the globe, while the importance of developing more vaccines to curb the threat of emerging diseases cannot be stressed enough. This was the overarching theme of the 16th Prestigious Lecture held by Wits University’s Faculty of Health Sciences, which was delivered by Professors Helen Rees and Shabir Madhi, at the Wits School of Public Health this week.
Wits Reproductive Health and HIV Institute (Wits RHI) and their partners are excited to announce the launch today of a study, ADVANCE, to evaluate a new antiretroviral drug combination for the treatment of HIV. The ADVANCE study is funded by the U.S. Agency for International Development and UNITAID through OPTIMIZE, a global partnership working to accelerate access to simpler, safer and more affordable HIV treatment.
The Wits Reproductive Health and HIV Institute (Wits RHI) today announced a new partnership with UNITAID. The partnership will support efforts to optimise antiretroviral treatment (ART) by investing in research and operations to expand access to new, more effective and affordable antiretrovirals that have fewer side effects and are better tolerated by people living with HIV.